Anderson Hoagland & Co. Purchases Shares of 78,494 Kenvue Inc. (NYSE:KVUE)

Anderson Hoagland & Co. acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 78,494 shares of the company’s stock, valued at approximately $1,656,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Huntington National Bank grew its holdings in Kenvue by 26.5% in the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after buying an additional 871 shares in the last quarter. ING Groep NV boosted its position in shares of Kenvue by 23.6% in the third quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after acquiring an additional 681,954 shares during the period. Everence Capital Management Inc. grew its stake in shares of Kenvue by 122.1% in the fourth quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock valued at $969,000 after acquiring an additional 24,950 shares in the last quarter. Saturna Capital Corp increased its position in Kenvue by 29.9% during the third quarter. Saturna Capital Corp now owns 1,334,860 shares of the company’s stock worth $30,875,000 after acquiring an additional 307,039 shares during the period. Finally, Tyler Stone Wealth Management raised its stake in Kenvue by 134.4% in the 3rd quarter. Tyler Stone Wealth Management now owns 49,050 shares of the company’s stock worth $1,135,000 after purchasing an additional 28,125 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

NYSE KVUE opened at $20.79 on Friday. The firm’s fifty day moving average price is $22.14 and its two-hundred day moving average price is $21.78. The stock has a market cap of $39.85 billion, a PE ratio of 37.79, a PEG ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same quarter in the prior year, the firm earned $0.31 EPS. The business’s revenue for the quarter was down .4% compared to the same quarter last year. On average, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.95%. Kenvue’s dividend payout ratio is presently 149.09%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Bank of America raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. UBS Group lowered their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Citigroup dropped their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.